Ensign Peak Advisors Inc Sells 78,284 Shares of Zoetis Inc. (NYSE:ZTS)

Ensign Peak Advisors Inc cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 21.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 292,863 shares of the company’s stock after selling 78,284 shares during the period. Ensign Peak Advisors Inc owned about 0.06% of Zoetis worth $47,716,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ZTS. Callahan Advisors LLC raised its stake in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares in the last quarter. CIBC Asset Management Inc increased its position in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Schroder Investment Management Group lifted its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the fourth quarter valued at approximately $1,764,000. Finally, Vanguard Group Inc. grew its stake in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after buying an additional 120,158 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,862 shares of company stock worth $312,254. 0.18% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on ZTS. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $212.13.

Zoetis Trading Down 1.1 %

NYSE:ZTS opened at $159.96 on Friday. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm’s fifty day moving average is $157.27 and its 200-day moving average is $166.22. The firm has a market cap of $71.37 billion, a P/E ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the company posted $1.38 EPS. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.